Company / Net Income
VYNE Therapeutics Inc. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$39.8M
FY2025
5-year range
-$255.6M / -$23.2M
FY2021-FY2025
Trend
-40.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$23M to -$40M over the past 2 years.
Based on SEC 10-K filings.
-$40M in FY2025.
Declined from -$23M to -$40M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 40.0% year-over-year.
- Peak net income was recorded in FY2018.
- Lowest net income in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$39.8M | -40.0% |
| FY2024 | -$28.5M | -22.6% |
| FY2023 | -$23.2M | +68.3% |
| FY2022 | -$73.3M | +71.3% |
| FY2021 | -$255.6M | -244.6% |
| FY2020 | -$74.2M | -155.1% |
| FY2019 | -$29.1M | -106.7% |
| FY2018 | -$14.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026